Tezepelumab treatment in patients with severe asthma led to fewer asthma exacerbations throughout all seasons compared to placebo, new data shows.
Tezepelumab was approved late last year by the Food and Drug Administration as an injection and add-on maintenance treatment to improve severe asthma symptoms when used with a patient’s current asthma medicine. It is the first treatment for severe asthma without biomarker or phenotype limitations.
The newest data on the monoclonal antibody came from a multi-center, randomized, double-blind, placebo-controlled study called NAVIGATOR.
The NAVIGATOR study included a total of 1059 patients. Patients between the ages of 12 and 80 years were randomized 1:1 to receive either tezepelumab (528) or placebo (531) subcutaneously every 4 weeks over the course of 52 weeks.
Investigators then examined the annualized asthma exacerbation rate (AAER) as well as a number of patients without exacerbations on a seasonal basis.
Get the full story at HCPlive.com.
Tezepelumab Severe Asthma
Go To Source For Respiratory Therapy Coverage
RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.
Go To Source For Respiratory Therapy Coverage
RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.
